Hello, everyone, and how are you this fine morning? Our day got off to a nice start, thanks to a warm and shiny sun enveloping the blissfully quiet Pharmalot campus. Our short people have departed for their respective destinations — the local schoolhouse and gainful employment — and we are busily tending to our own usual tasks — brewing cups of stimulation and hunting for items of interest. This, in fact, brings us to the menu of tidbits assembled below. So please indulge and dig in. Hope you have a smashing day and, as always, do keep in touch. …
Activists gathered for AIDSWatch, the nation’s largest annual constituent-based national HIV/AIDS advocacy conference, heckled CDC director Dr. Robert Redfield after he sidestepped questions about the exclusivity and cost of the HIV prevention drug Truvada, the New York Daily News tells us. Gilead Sciences (GILD) licenses and makes the pill, but its exclusivity rights means people are paying as much as $1,600 each month for a drug that activists say should be available for $6. AIDS activists want the CDC to pursue royalties.
About the Author Reprints
